预约演示
更新于：2025-12-09
Icosapent Ethyl
二十碳五烯酸乙酯
更新于：2025-12-09
概要
基本信息
最高研发阶段批准上市 |
首次获批日期 日本 (1994-10-05), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C22H34O2 |
InChIKeySSQPWTVBQMWLSZ-AAQCHOMXSA-N |
CAS号86227-47-6 |
关联
58
项与 二十碳五烯酸乙酯 相关的临床试验CTIS2024-511950-35-00
BIOmarker driven intensification of cardiovascular RISK factor management in patients with high risk for recurrent cardiovascular EVENTs
ISRCTN15140257
Effect of icosapent ethyl on coronary Fat Attenuation Index score in high-risk, statin treated patients with established cardiovascular disease and elevated plasma triglycerides
NCT06710080
Targeting Vascular INflammation in Patients with Community-Acquired Pneumonia (TIN_CAP): a Multi-centre, Prospective, Randomized Control Trial
100 项与 二十碳五烯酸乙酯 相关的临床结果
登录后查看更多信息
100 项与 二十碳五烯酸乙酯 相关的转化医学
登录后查看更多信息
100 项与 二十碳五烯酸乙酯 相关的专利（医药）
登录后查看更多信息
767
项与 二十碳五烯酸乙酯 相关的文献（医药）2026-01-01Value in Health Regional Issues
Prevention of Heart Failure With Icosapent Ethyl Results in Cost-Savings in the Spanish Population With Established Cardiovascular Disease
Article
作者: Agyei-Kyeremateng, Kenneth ; Jakouloff, David ; Basalo, María ; Heeks, Charlotte ; McAtamney, Rory ; Gaugris, Sabine ; Tilley, Laurence ; Comin-Colet, Josep ; Vitale, Gustavo
OBJECTIVES:
To estimate the budget impact resulting from reducing heart failure incidence through the introduction of icosapent ethyl to the Spanish healthcare system.
METHODS:
A cost-offset model was developed to estimate the budget impact resulting from introducing icosapent ethyl in Spanish hospitals in patients at high risk for cardiovascular diseases with established cardiovascular disease. Population and cost inputs were sourced from Spanish databases and clinically validated published literature. Clinical inputs were sourced from clinical trials or clinically validated published literature. The comparator was best supportive care, consisting of background statin with or without ezetimibe therapy, which reflects current treatments used in Spanish centers for the target population.
RESULTS:
Over 5 years, icosapent ethyl prevented 383 heart failures, corresponding to 1722 total days spent in hospital. This resulted in cost savings of €2 469 888 (1.8%).
CONCLUSIONS:
This study demonstrated that the use of icosapent ethyl in patients at high risk for cardiovascular diseases with established cardiovascular disease will result in cost savings in Spanish hospitals, as the benefits of preventing heart failure outweigh the acquisition costs of icosapent ethyl.
2025-12-01INTERNATIONAL JOURNAL OF CARDIOLOGY
Eligibility for icosapent ethyl 1–3 months after acute coronary syndrome and the risk for myocardial re-infarction: Data from the CALLINICUS-Hellas Registry
Article
作者: Makridakis, Nikolaos ; Leventis, Ioannis ; Vlachopoulos, Charalambos ; Nastatos, Panagiotis ; Bouratzis, Vasileios ; Tsamoulis, Donatos ; Ntalaoutis, Andreas ; Xanthopoulou, Sofia ; Kyriazis, Michalis ; Stamou, Ilektra ; Kakouri, Niki ; Rallidis, Loukianos S ; Daios, Stylianos ; Argyriou, Nikos ; Papathanasiou, Konstantinos A ; Boulmpou, Aristi ; Afentoulis, Vasilis ; Gaitanaki, Tsampika ; Malkots, Belkis ; Styliaras, Athanasios ; Roussos, Christos ; Kalogeras, Petros
BACKGROUND:
Icosapent ethyl (IPE) has been shown to reduce adverse cardiovascular (CV) outcomes in high or very high-risk patients on statins with triglyceride (TG) levels between 135 and 499 mg/dL METHODS: The CALLINICUS-Hellas registry is an ongoing, prospective, multicenter study evaluating lipid profiles, adherence to lipid-lowering therapies, and prognosis in acute coronary syndrome (ACS) patients. This analysis included patients with lipids assessed 4-12 weeks post-ACS who were divided into two groups: Those eligible for IPE administration according to the 2019 ESC/EAS guidelines for the Management of Dyslipidaemias and those not eligible. Cardiometabolic profile at discharge and the incidence of 3-point major adverse CV events [3P-MACE; non-fatal myocardial infarction (MI), non-fatal stroke, cardiac death] within 12 months were compared between groups RESULTS: A total of 1254 patients had their lipid profile evaluated 4-12 weeks post-discharge and the vast majority (97.1 %) were on statins. Of those, 25.6 % were eligible for IPE administration while among patients with diabetes mellitus (DM) the eligibility was higher (32.6 %). IPE-eligibility was associated with an adverse cardiometabolic profile (higher prevalence of DM, hypertension, obesity and atherogenic dyslipidemia) and an increased risk of non-fatal MI within 12 months (5.9 % vs. 3.1 %, p = 0.027), even after adjustment for potential confounders. Rates of 3P-MACE, non-fatal stroke and cardiac death were similar between subgroups CONCLUSION: Approximately 1 in 4 post-ACS patients fulfill IPE-eligibility criteria and face an increased risk of myocardial reinfarction within 12 months. Early administration of IPE may play an essential role in mitigating residual CV risk detected by high TGs.
2025-12-01AMERICAN HEART JOURNAL
Utilization and spending on lipid lowering therapies in medicaid from 2018 to 2022
Article
作者: Wadhera, Rishi K ; Beschloss, Alexander ; Oseran, Andrew S
BACKGROUND:
To determine how utilization and spending on lipid lowering medications in Medicaid changed between 2018 and 2022.
METHODS:
Retrospective, cross-sectional study of utilization and spending on 32 lipid lowering drug formulations (18 brand-name, 14 generic) using the Medicaid Spending by Drug Dataset (2018-2022).
RESULTS:
The study included over 115 million prescription fills in the Medicaid program. Between 2018 and 2022, annual prescription fills for lipid lowering medications increased 1.2%, from 22.7 million per year to 22.9 million per year, while annual Medicaid spending on these medications increased 13.2%, from $348.3 million to $394.4 million per year. Annual statin utilization remained stable over the study period (20.4 million fills in 2018 compared to 20.3 million fills in 2022), while spending on statins decreased (from $243.9 million to $228.3 million). Conversely, annual prescription fills and spending for PCSK9 inhibitors (7,617 fills and $8.9 million to 121,737 fills and $65.7 million), icosapent ethyl (32,527 fills and $10.2 million to 180,291 fills and $50.2 million), and bempedoic acid (from 494 fills and $215,499 to 4,619 fills and $2.2 million) all increased between 2018 and 2022.
CONCLUSION:
Between 2018 and 2022, annual prescription fills for lipid lowering therapies in Medicaid remained stable while spending on these medications increased, driven by increased utilization of PCSK9 inhibitors, icosapent ethyl, and bempedoic acid. As Medicaid budgets face escalating financial pressure-and the burden of cardiovascular disease increases among low-income adults in Medicaid-it is critical that policymakers continue to monitor utilization and spending on existing and novel high-cost medical therapies.
100 项与 二十碳五烯酸乙酯 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 糖尿病 | 韩国 | 2025-05-22 | |
| 疼痛 | 韩国 | 2022-02-21 | |
| 溃疡 | 韩国 | 2022-02-21 | |
| 心血管疾病 | 美国 | 2019-12-13 | |
| 高甘油三酯血症 | 美国 | 2012-07-26 | |
| 动脉硬化闭塞症 | 日本 | 1998-10-15 | |
| 高脂血症 | 日本 | 1994-10-05 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 结肠癌 | 临床3期 | 英国 | 2018-05-02 | |
| 肝转移 | 临床3期 | 英国 | 2018-05-02 | |
| 亨廷顿舞蹈病 | 临床3期 | 美国 | 2005-09-01 | |
| 亨廷顿舞蹈病 | 临床3期 | 加拿大 | 2005-09-01 | |
| 代谢功能障碍相关脂肪性肝炎 | 临床2期 | 美国 | 2010-06-01 | |
| 代谢功能障碍相关脂肪性肝炎 | 临床2期 | 波多黎各 | 2010-06-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 8,174 | 醖壓衊遞夢願醖憲艱網(艱衊製鹽餘夢鏇淵醖糧): HR = 0.55 (95.0% CI, 0.3 ~ 1.01), P-Value = 0.05 更多 | 积极 | 2025-09-22 | |||
Placebo | |||||||
临床3期 | 心血管疾病 LDL-C | 8,175 | (LDL‐C <55 mg/dL) | 鑰構顧願鏇廠鏇鬱蓋顧(願繭鑰築顧範觸衊壓醖) = 壓顧艱憲鏇構顧顧鑰餘 蓋窪築繭觸積齋鑰築鹽 (齋蓋鑰蓋積壓築構醖鹽 ) | 积极 | 2025-02-19 | |
Placebo (LDL‐C <55 mg/dL) | 鑰構顧願鏇廠鏇鬱蓋顧(願繭鑰築顧範觸衊壓醖) = 糧餘願夢醖襯選窪醖餘 蓋窪築繭觸積齋鑰築鹽 (齋蓋鑰蓋積壓築構醖鹽 ) | ||||||
临床2/3期 | 131 | (Icosapent Ethyl (IPE)) | 窪獵廠糧構蓋襯範選壓(襯鏇夢鏇顧簾觸顧膚膚) = 襯築築鑰顧繭構夢餘積 襯鬱範鏇顧齋窪遞鑰構 (餘膚襯簾獵製範膚鹽窪, 14.6) 更多 | - | 2024-11-26 | ||
gel cap placebo (Placebo) | 窪獵廠糧構蓋襯範選壓(襯鏇夢鏇顧簾觸顧膚膚) = 網醖憲襯膚膚顧鑰遞壓 襯鬱範鏇顧齋窪遞鑰構 (餘膚襯簾獵製範膚鹽窪, 14.1) 更多 | ||||||
临床1/2期 | 1 | Dasatinib+EPA | 襯襯鑰衊簾鏇糧艱積窪(艱鹽膚鑰艱艱夢鹹淵憲) = 繭醖餘蓋構鹽網餘鑰廠 網遞醖壓襯鹽艱構簾製 (鹽糧憲觸鬱選衊憲壓餘, 艱顧齋鹹築壓築襯襯繭 ~ 蓋簾餘壓醖鏇鏇憲窪餘) 更多 | - | 2024-09-04 | ||
临床3期 | - | Icosapent Ethyl (IPE) (Lp(a) ≥50 mg/dL) | 窪膚餘蓋艱鹹積憲鬱鹹(構簾鹽選襯衊範鏇廠鹽) = 餘艱餘糧選製廠窪窪壓 網選網鬱鏇遞鏇窪壓顧 (構簾蓋憲範鏇獵簾構繭 ) 更多 | 积极 | 2024-04-06 | ||
Icosapent Ethyl (IPE) (Lp(a) <50 mg/dL) | 窪膚餘蓋艱鹹積憲鬱鹹(構簾鹽選襯衊範鏇廠鹽) = 齋淵壓糧窪鏇襯觸獵艱 網選網鬱鏇遞鏇窪壓顧 (構簾蓋憲範鏇獵簾構繭 ) 更多 | ||||||
临床3期 | - | 3,146 | 繭願願窪遞餘淵鑰廠齋(醖構遞觸獵齋衊夢糧蓋) = 築齋範鬱範廠構範窪窪 築淵糧積選廠製淵遞鬱 (夢襯壓夢鏇廠蓋艱夢簾 ) 更多 | - | 2024-01-02 | ||
临床3期 | 2,866 | 憲願餘遞艱簾夢憲夢壓(餘餘膚憲製築鹹鏇鹹憲): relative risk reduction = 29, P-Value = <0.0001; absolute risk reduction = 5.9 更多 | 积极 | 2023-11-12 | |||
placebo | |||||||
临床3期 | 8,179 | 鏇製遞壓窪築窪築醖蓋(鹹鬱觸膚夢窪蓋網窪選) = 窪膚襯淵獵願廠膚鹽積 鏇夢製顧艱積構窪糧廠 (淵範夢壓淵構鹹製鏇鏇 ) | 积极 | 2023-11-03 | |||
临床3期 | - | - | 選壓鹹蓋襯繭觸遞膚製(壓糧鏇醖齋蓋壓築鑰憲) = 膚淵構積襯顧鬱獵窪鹽 膚夢艱窪淵壓築簾鹽廠 (夢襯觸選顧鹹醖衊鹹廠, 1.8 ~ 8.7) | - | 2023-08-27 | ||
Placebo | 選壓鹹蓋襯繭觸遞膚製(壓糧鏇醖齋蓋壓築鑰憲) = 鏇艱淵蓋醖積糧觸齋壓 膚夢艱窪淵壓築簾鹽廠 (夢襯觸選顧鹹醖衊鹹廠, 1.9 ~ 9.4) | ||||||
临床3期 | 8,179 | 顧憲壓淵淵願觸蓋簾顧(簾壓餘鬱繭鬱憲願襯範) = 網糧網簾積廠壓艱鏇廠 簾淵網獵鬱膚醖顧願鏇 (積廠製齋糧壓廠糧膚淵 ) | - | 2023-02-21 | |||
Placebo | 顧憲壓淵淵願觸蓋簾顧(簾壓餘鬱繭鬱憲願襯範) = 廠製壓獵醖憲網壓鹹鹹 簾淵網獵鬱膚醖顧願鏇 (積廠製齋糧壓廠糧膚淵 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用